zilongwang/ReadingBank huggingface dataset:
Supplementary data The raw inputs used to develop the systems representation of the site water balance are presented below. Tasks and tailings facility are distinguished using grey headings; stores are distinguished using blue headings. For quantification of the flows, site documentation were used as reported in the year 2010. For the characteristics of the storage facilities (e.g. surface area/volume), site reports from 2008 and 2012 were used. The final column indicates the confidence in the accuracy of the values. Variable Data source Units Value adopted Confidence Task - Processing plant Process plant sources Water with feed Calculated from site documentation ML/month 27 Medium Underground dewatering to worked water store Flows calculated from site documentation. Underground to process thickener 152 Medium Worked water store to process plant Assume that make-up comes from process pond. (Make up required) = (Coarse tails) + (fine tails) - (UG water) - (Water with Feed) ML/month 286 Low Process plant outputs Water in product Site documentation ML/month 0 N/A in fine tailings See TSF inputs N/A in coarse tailings Flows calculated from site documentation. Dry coarse tailings is 3,830,785t/year with 10% moisture ML/month 35 Medium Discharge Estimate from discussion with site ML/month 152 Low Site Object - Tailings Tailings properties surface area Site documentation ha 125 High Void volume Site documentation (volume of new + old tailings) ML 2500 High Tailings input Fine From site documentation, dry tonnes tailings flow is 3,443,315t/yr with 60% moisture content 430 Medium Catchment area Site documentation (catchment area of new + old tailings) ha 305 High Proportion disturbed Site documentation (assume all disturbed as catchment is stockpile/mine) % 1 High Tailings outputs Tailings loss (via entrainment) Site documentation - assume 25% tailings entrainment. Dry solids flow = 3.44Mtpa. Therefore solids + water entrained = 4.59Mtpa ML/month 96 Low Tailings decant return See WWR input Underdrains to Worked Water Store See WWR input
Table S3 Water quality parameters of the secondary effluent Water type Hardness (CaCO3 mg/L) Alkalinity (CaCO3 mg/L) SS pH TOC (mg C/L) COD (mg O2/L) UV254 Secondary effluents 223 167.3 24 7.28 7.119 30.3 0.162
Table S4 Mass spectra data and proposed structure of identified intermediates Molecular formula Retention time (min) Molecular weight Mass (m/z) ppm Molecular structure Molecular unsaturation Structural unsaturation ACV C8H11N5O3 11.16 225.0862 226.0935 [M+H]+/ 224.0789 [M-H]- -0.4 6 6 P-1 C7H11N3O3 2.87 185.0800 186.0869 [M+H]+ 2.26 4 4 P-2 C8H9N5O5 3.09 255.0604 278.0496 [M+Na]+ -0.5 7 7 P-3 C5H5N5O 11.01 151.0494 152.0570 [M+H]+ -1.3 6 6 P-4 C5H4N4O2 11.19 152.0334 153.0409 [M+H]+ -1.3 6 6 P-5 C5H11N3 27.64 113.0953 114.0923 [M+H]+ 2.42 2 2
P-6 C6H4N4O4 28.11 196.0233 197.0305 [M+H]+ 2.26 7 7 P-7 C7H9N5O7 43.48 275.0496 276.0580 [M+H]+ -1.91 6 6 P-8 C8H11N5O7S 35.05 321.0379 322.0452 [M+H]+ -0.4 6 6 P-9 C7H11N5O3 45.71 213.0862 214.0896 [M+H]+ -2.06 5 5 P-10 C8H10N4O4 8.60 226.0702 225.0629 [M-H]- 1.45 6 6 P-11 C13H12N10O6 30.36 404.0941 403.1011 [M-H]- -6.9 13 13 P-12 C16H20N10O6 37.68 448.1567 447.1489 [M-H]- -0.4 12 12 P-13 C9H18N6 44.68 210.1593 209.1532 [M-H]- -5.26 4 4
then loaded onto the inserts at 1×105 cells/200 μL for each assay. Conditioned medium from adenoviral transduction assays was placed in the bottom chamber (500 l). After 1 hour of incubation at with 5% CO2, cells that migrated to the lower chamber were collected; the number of cells that migrated from the top to the bottom compartment was measured by counting. Respiration experiments on intact cells. THP-1 macrophages and SGBS adipocytes were obtained and cultured as described (3, 4). Cells were introduced in the 2 mL chamber of an Oroboros-2k™ respirometer (Oroboros® Instruments GmbH Corp, ) to perform high-resolution respirometry studies. Routine respiration was assessed under conventional culture conditions at 37 oC. To study Leak respiration, oligomycin (inhibitor of ATP synthase) was added to the chamber. To study electron transfer system (ETS) capacity, FCCP was titrated until reaching maximal respiration. Subsequently, complex I was inhibited by adding rotenone to the chamber and finally antimycin A was added to inhibit oxidative phosphorylation at the level of complex III. The oxygen consumption that remains is considered residual oxygen consumption (ROX). ROX values are subtracted from previous oxygen measurements to calculate oxygen flux at the different respiratory states. In this case, oxygen consumption values were normalized by total number of cells. Lactate and succinate release. Extracellular lactate and succinate measurements were performed on conditioned medium. THP-1 or SGBS cells were plated, infected with PTG or GFP, and supernatant media were collected after 24 hours. Supernatant from at least three independent experiments was assayed using a lactate assay kit (BioVision, Mountain View, CA) and succinate assay kit (BioVision, Mountain View, CA) following the manufacturer´s instructions. Animals. Adipose tissue gene expression analysis was performed on Wild-type (WT) and homozygous PTG KO male mice maintained on a C57BL/6J background (5). All mice were maintained in temperature- and humidity-controlled conditions with a 12-h light/dark cycle and
SUPPORTING INFORMATION Preparation and stability of dexamethasone-loaded polymeric scaffolds for bone regeneration processed by compressed CO2 foaming§ Leticia Goimila, Philip Jaegerb, Inés Ardaoc, José Luis Gómez-Amozaa, Angel Concheiroa, Carmen Alvarez-Lorenzoa, Carlos A García-Gonzáleza aDepartamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+D Pharma group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain bHamburg University of Technology (TUHH), Eißendorfer Str. 38, D-21073, Hamburg, Germany cBioFarma Research Group, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain *Corresponding author: carlos.garcia@usc.es; phone: +34 881 815252; fax: +34 981 547148. §The work described in this paper is the subject of the PCT-patent application WO 2017013288 A1 filed by the Universidade de Santiago de Compostela.
Covariance Parameter Standard Error ICC (95% CI) MOR (95% CI) Total Cohort Intercept-only 1.4674 0.1474 0.308 (0.264 – 0.348) 3.18 (2.82 – 3.54) Comorbidity-adjusted 1.3818 0.1406 0.296 (0.252 – 0.335) 3.07 (2.73 – 3.41) Comorbidity and Demographic-adjusted 1.1190 0.1185 0.254 (0.212 – 0.291) 2.74 (2.46 – 3.03) Medicare Cohort Intercept-only 1.2945 0.1341 0.282 (0.239 – 0.321) 2.96 (2.63 – 3.29) Comorbidity-adjusted 1.3863 0.1435 0.296 (0.251 – 0.336) 3.07 (2.73 – 3.43) Comorbidity and Demographic-adjusted 1.1111 0.1194 0.252 (0.210 – 0.290) 2.73 (2.44 – 3.02)
-2 Log Likelihood AIC AIC Portion vs. Comorbidity Model C-Statistic Hosmer-Lemeshow Χ2 Hosmer-Lemeshow p Full Cohort Intercept-only 15280.60 --- --- --- --- Comorbidity --- 0.821 (0.812 – 0.830) 428.16 <0.001 DNR + Comorbidity 12767.95 12825.95 0.168 0.841 (0.833 – 0.849) 605.96 <0.001 DNR Slope + Comorbidity 12758.80 12818.80 0.170 0.845 (0.837 – 0.853) 570.56 <0.001 Medicare Cohort Intercept-only 12842.72 12846.72 --- --- --- --- Comorbidity 11337.28 --- 0.803 (0.793 – 0.813) 299.75 <0.001 DNR + Comorbidity 10910.97 10968.97 0.196 0.825 (0.816 – 0.835) 424.21 <0.001 DNR Slope + Comorbidity 10898.30 10958.30 0.201 0.832 (0.822 – 0.841) 433.70 <0.001
N Correlation (95% CI) P Total Cohort Overall 55,865 0.470 (0.375 – 0.555) <0.001 DNR Rate Quartile 1 – 0 – 3.9% 14,338 0.179 (-0.055 – 0.395) 0.13 DNR Rate Quartile 2 – 3.9 – 8.7% 14,631 0.089 (-0.144 – 0.312) 0.46 DNR Rate Quartile 3 – 8.7 – 20.0% 14,505 0.204 (-0.035 – 0.420) 0.09 DNR Rate Quartile 4 – > 20.0% 12,391 0.236 (0.011 – 0.438) 0.04 Medicare Cohort Overall 40,414 0.353 (0.246 – 0.452) <0.001 DNR Rate Quartile 1 – 0 – 5.7% 9.532 0.158 (-0.081 – 0.381) 0.19 DNR Rate Quartile 2 – 5.7 – 12.0% 10,174 0.103 (-0.136 – 0.330) 0.39 DNR Rate Quartile 3 – 12.0 – 24.7% 10,938 0.135 (-0.103 – 0.359) 0.27 DNR Rate Quartile 4 – > 24.7% 9,770 0.132 (-0.108 – 0.358) 0.28
Fig. S3. CORM-3 inhibits cell growth and is bactericidal to E. coli MG1655 cell cultures grown on glucose defined minimal medium (GDMM). (a) Cell growth, assessed by monitoring culture optical density (OD600), in the absence of CORM-3 (closed circles) or after the addition of 15 μM (dashed line, closed squares), 30 μM (open squares), 60 μM (dashed line, closed triangles) or 120 μM (open triangles) CORM-3. Growth was completely inhibited at ≥ 30 μM CORM-3. (b) Culture viability, assessed via colony forming units per mL (CFU mL-1), in the absence of CORM-3 (black bars) or after the addition of 15 μM (white bars), 30 μM (light grey bars), 60 μM (dark grey bars) or 120 μM (black/grey bars) CORM-3. Arrows indicate where the culture viability was undetectable. CORM-3 caused a dose-dependent increase in cell killing, with a complete loss in culture viability at 120 min at ≥ 60 μM CORM-3. Data represent 3 biological repeats ± SD. Supplementary Data Fig. S4
Table S1 Concentration of select pharmaceuticals and artificial sweeteners in wastewater (ng/L) from Indian ditches analyte LOQ Cooum River Cooum River Patna Sewage Sanganur Pallam, Coimbatore Coimbatore Landfill Leachate (ng/g dw) QTP 0.5 18.2 27.4 44.2 3.80 1.91 NQTP 5.0 9.44 8.24 5.28 24.6 2.23 APPZ 0.5 ND ND ND ND 5.11 DAPPZ 0.5 ND ND ND ND 1.04 sedatives-hypnotics-anxiolytics LZP 0.5 ND 72.4 ND ND ND APZ 5.0 6.96 11.4 4.20 ND ND AHA 5.0 ND ND ND ND ND DZP 1.0 7.28 4.50 7.76 ND 1.86 OXZP 1.0 17.7 ND ND 12.6 ND NDZP 1.0 16.7 7.58 8.66 3.40 ND CBZ 1.0 214 902 370 83.6 20.1 antidepressants VLF 0.1 117 40.6 17.4 50.6 ND BPP 0.5 ND ND 6.72 ND 7.82 STL 1.0 52.2 9.70 22.6 3.09 12.7 NSTL 10 ND ND ND ND ND CLP 1.0 18.8 5.88 12.4 ND ND DCLP 20 ND ND ND ND ND antihypertensions PPN 1.0 36.0 37.4 35.2 12.3 10.3 ANL 10.0 3180 2180 632 508 268 DTZ 1.0 ND ND ND ND 5.56 DAD 0.5 22.6 22.4 7.54 1.98 3.66 VPM 0.5 ND 46.6 1.68 2.22 ND NVP 0.5 1.73 0.92 1.47 ND 2.17 TCS 10 1440 352 574 1500 106 TCC 5.0 6180 1970 1850 1470 188
After 200 cycles α-Fe2O3 NPs 9.03 92.84 28.25 30.6 4.35×10−16 α-Fe2O3 NFs 3.51 29.95 25.34 10.4 3.37×10−15 γ-Fe2O3@C NFs 2.87 22.44 22.75 9.7 5.06×10−15 After 200 cycles, the σ values of three samples decreased significantly and NFs shows the lower value than that of other electrodes, indicating the efficient diffusion of Li+ into the electrode materials. Besides, the γ-Fe2O3@C NFs electrode presents the Li+ diffusion coefficient of 5.06×10−15 cm2 s−1, which is higher than that of the α-Fe2O3 NFs (3.37×10−15 cm2 s−1) and NPs (4.35×10−16 cm2 s−1); this explains the good Li ion diffusion ability of the γ-Fe2O3@C NFs.
ARGs Sequence (5’-3’) Thermal profile Cycles Detection format Reference 95 °C 3 min 95 °C 15 s, 60 °C 45 s 40 SYBR Green Fierer et al. (2005) Intl1 95 °C 3 min 95 °C 15 s, 60 °C 45 s 40 TaqMan Barraud et al. (2010) ermB 95 °C 3 min 95 °C 15 s, 60 °C 45 s 40 SYBR Green Knapp et al. (2010) sul1 ccgttggccttcctgtaaag ttgccgatcgcgtgaagt 95 °C 3 min 95 °C 15 s, 60 °C 45 s 40 TaqMan Heuer and Smalla (2007) sul2 cggctgcgcttcgatt cgcgcgcagaaaggatt 95 °C 3 min 95 °C 15 s, 60 °C 45 s 40 TaqMan Heuer et al. (2008) tetW 95 °C 3 min 95 °C 15 s, 59 °C 45 TaqMan Walsh et al. (2011) Text S1. Indicatory parameters of WWTP influence.
107 Shrub Height > 3.0 meters 108 Forest Height 0 to 5 meters 109 Forest Height 5 to 10 meters 110 Forest Height 10 to 25 meters 111 Forest Height 25 to 50 meters Appendix C. Tables and Figures for the climate prediction models. C.1 Percent contributions of environmental predictors for the current climate and future climate species distribution models for the band-tailed pigeon (Patagioenas fasciata) in New Mexico on satellite tracking occurrence data. Our models include current and future climate scenarios for years 2050 and 2070, including representative concentration pathways (RCP) 4.5 and 8.5, which represent optimistic and pessimistic future atmospheric CO2 concentration scenarios, respectively. Environmental predictor Percent contribution Current RCP4.5 2050 RCP8.5 2050 RCP4.5 2070 RCP8.5 2070 Annual precipitation 58.6 54.9 54.7 55.1 55.9 Temperature seasonality 17.9 20.5 16.2 20.5 18.9 Mean diurnal range 10.6 11.6 13.4 11.6 11.2 Min temperature coldest month 6.6 6.2 7.6 6.5 7.2 Mean temperature driest quarter 6.3 6.7 8 6.3 6.7
30°C 22°C 7°C Vibrio Total coliforms Fecal coliforms E. coli Enterococci 102.25 ± 100.79 106.66 ± 100.60 106.81 ± 100.47 106.66 ± 100.31 105.04 ± 100.03 105.38 ± 100.68 104.22 ± 100.72 104.22 ± 100.37 103.19 ± 100.14 102.50 ± 100.61 106.66 ± 100.60 106.81 ± 100.47 106.66 ± 100.31 105.04 ± 100.03 105.38 ± 100.68 104.22 ± 100.72 104.22 ± 100.37 103.19 ± 100.14 102.50 ± 100.61 103.82 ± 100.37 104.83 ± 100.23 104.92 ± 100.21 104.74 ± 100.41 103.25 ± 100.26 103.83 ± 100.60 103.28 ± 100.32 102.91 ± 100.22 102.91 ± 100.22 102.83 ± 100.16 107.65 ± 100.89 107.78 ± 100.82 106.88 ± 100.25 105.16 ± 100.35 104.34 ± 100.58 103.78 ± 100.22 103.78 ± 100.22 103.61 ± 100.37 103.82 ± 100.37 9.33×100 1.66×100 1.32×100 9.12×10-2 3.63×10-1 3.63×10-1 2.63×100 2.09×101
For a diabetes II patient of 70 kg in weight, ca. 6 mg of insulin@ZIF-8 are needed on a daily basis. As follows, this amount is well below the 30 µg mL-1 threshold for ZIF-8 (that is the ~38 mg threshold for the insulin@ZIF-8 biocomposite): Fig. A1 – MTT cell viability of Raw 264.7 and 3T3 cells after 5 days exposure to various amounts of 2-methylimidazole (2-mIM). Fig. A2 – Fluorescence images detecting ROS production in MG-63 cells at different ZIF-8 concentrations. Fig. A3 – Fluorescence activated cell sorting analysis for MG-63 cells after three days incubation with (a) 0 µg mL-1, (b) 30 µg mL-1, and (c) 100 µg mL-1 of ZIF-8. Fig. A4 – Cell cycle analysis of six different cell lines, indicating cell population present in the G2 / M stage at different ZIF-8 concentrations.
Fig. S3. Three-dimensional intrinsic fluorescence spectra for (a) pure PSA (2 μM), (b) PSA (2 μM) + C12-E2O-C12 (2.459 μM), (c) PSA (2 μM) + C14-E2O-C14 (2.459 μM) and (d) PSA (2 μM) + C16-E2O-C16 (2.459 μM).
0 12.9% 21.5% 25.8% Unspinnable Table S2. SEM images of the as-synthesized CHNBs@PCNFs with various heating rates, but with a constant weight ratio (WR) of 21.5% of LiN3 to PVA in the electrospinning precursor. Rate (oC SEM images Rate (oC SEM images
Supplemental Appendix B. Distribution of PSA and Gleason score All (N=1,088) RP (N=661) RT (N=181) ADT (N=105) AS (N=141) p PSA, (median, IQR) 6.2 (4.7-10) 5.6 (4.4-7.8) 8.9 (5.7-15.4) 23.6 (10.6-44) 6.0 (4.8-8.5) <0.0001 n (row %) Gleason score 4-6 3+4 4+3 8 9-10 602 277 117 64 27 392 (65.1) 177 (63.9) 65 (55.6) 20 (31.3) 7 (25.9) 82 (13.6) 58 (20.9) 23 (19.7) 14 (21.9) 4 (14.8) 11 (1.8) 27 (9.8) 25 (21.4) 27 (42.2) 14 (51.9) 117 (19.4) 15 (5.4) 4 (3.4) 3 (4.7) 2 (7.4) <0.0001 Note: PSA was not available for 9 patients; Gleason score was not available for 1 patient.
MSM (0.65,0.32) Non-PWID, non-PWUD Female (0.17,0.4) Heterosexual male (0.083,0.75) MSM (0.5,0.5) (3, 18) % of PWID partners: PWID 0.80 % of PWID partners: PWUD 0.18 % of PWUD partners: PWUD 0.60 % of MSM partners: MSM 0.85 % of partners: 1.00 Age selection see tables below (19) Characterizing partnerships % of relationships that are casual 0.342 (20) % of PWID partners that are injecting only 0.600 (3)
A summary of systems used for text mining of cancer-related information Study System name Disease Document type NLP task Methods Resources Framework Tools Licence [5] colorectal cancer colonoscopy and pathology reports IE classification rule-based UMLS GATE [14] breast cancer mammography reports classification linear least squares fit BI-RADS [16] MedLEE breast cancer surgical pathology reports IE rule-based patented [17] breast cancer mammography reports classification Bayesian network BI-RADS [18] breast cancer mammography reports classification rule-based BI-RADS UMLS [19] breast cancer mammography reports classification inductive logic programming [20] ClearForest breast cancer pathology reports IE ICD-9 CPT commercial [21] SCENT breast cancer prostate cancer pathology reports classification rule-based SNOMED CT SAS freely available [23] MedTAS/P colon cancer pathology reports IE rule-based ML ICD-O FMA UIMA open source [25] colorectal cancer EMRs IE rule-based [26] ARC colorectal, prostate and lung cancer imaging and pathology reports IR CRF maximum entropy UMLS ICD-9 UIMA MALLET open source [28] colorectal cancer EMRs IE rule-based
Study System name Disease Document type NLP task Methods Resources Framework Tools Licence [59] caTIES cancer surgical pathology reports IR rule-based NCI Thesaurus GATE open source [64] CSIS lung cancer pathology reports classification SVM UMLS [68] cancer surgical pathology reports IE rule-based UMLS [81] LEXIMER radiology reports IE rule-based commercial [89] cTAKES EMRs ML UIMA open source [94] cancer hospital discharge summaries NER ML
Human blood dilutions Dilution factor 1 101 102 103 104 105 106 Combur3 Test® E +++ +++ ++ ++ + + - Phenolphthalein DischapsTM +++ ++ + - - - - Leuco-Malachite DischapsTM +++ +++ ++ + + - - Hemastix® +++ +++ + + + + - Notes: See Table A1 notes for results interpretation. Table A3. Quantification of Combur3 Test® E exposed and unexposed bloodstains. Combur3 Test® E exposure Mean DNA quantification results ([DNA]) Human blood dilutions Dilution factor 1 101 102 103 104 105 106 Combur3 Test® E exposed bloodstains IC≤30 Ct IC≤30 Ct [DNA]≥LoD IC≤30 Ct [DNA]<LoD IC≤30 Ct [DNA] U IC≤30 Ct [DNA] U IC≤30 Ct [DNA] U IC≤30 Ct Combur3 Test® E unexposed bloodstains [DNA]≥ LoD IC≤30 Ct [DNA]≥ LoD IC≤30 Ct [DNA]≥ LoD IC≤30 Ct [DNA]≥ LoD IC≤30 Ct [DNA]< LoD IC≤30 Ct [DNA] U IC≤30 Ct [DNA] U IC≤30 Ct Diluted bloodstains on simulated evidences Dilution factor 103 104 105 Combur3 Test® E exposed bloodstains [DNA]≥ LoD IC≤30 Ct [DNA]< LoD IC≤30 Ct [DNA] U IC≤30 Ct Combur3 Test® E unexposed bloodstains [DNA]≥ LoD IC≤30 Ct [DNA]< LoD IC≤30 Ct [DNA] U IC≤30 Ct Human bloodstains on evidences from real caseworks (undiluted, always visible to the eye) Combur3 Test® E exposed bloodstains [DNA]≥LoD IC≤30 Ct
Figure S1. Density of states plot for pristine, Ca, In and Ca-In co-doped SnTe. Figure S2. Electronic structure of a) Sn15CaTe16, b) Sn14CaInTe16, where Ca is in zinc blende site.
Figure S3. Variation of ZT with temperature in Sn1.04-y-xCayInxTe. To test the effect of ratio of co-dopant concentrations in SnTe, we carried out synthesis of a series of samples with varying ratios of Ca and In. Initially, to the optimized concentration of self compensated SnTe (i.e. Sn1.04Te) we added Ca in increasing amounts. We found that at 8 mol % of Ca, maximum ZT was achieved. Now, to this composition, we added In in increasing amounts. We see that at 8 mol % of Ca and 4 mol % of In, a maximum ZT of 1.65 is achieved further confirming the chosen 2:1 Ca:In ratio was appropriate for the study to gain maximum synergistic effect.
Date Action Taken (if any) Signed Appendix 3: Signs of Abuse Physical Signs Changes in Behaviour Physical Abuse unexplained bruising, marks or injuries on any part of the body multiple bruises- in clusters, often on the upper arm, outside of the thigh cigarette burns human bite marks broken bones scalds, with upward splash marks, multiple with a clearly demarcated edge fear of parents being approached for an explanation aggressive behaviour or severe temper outbursts flinching when approached or touched reluctance to get changed, for example in hot weather depression withdrawn behaviour running away from home Emotional
Speech disorders Delayed physical development Substance abuse Ulcers, severe allergies Failure to thrive Self-harm neurotic behaviour e.g. sulking, hair twisting, rocking being unable to play fear of making mistakes sudden speech disorders self-harm fear of parent being approached regarding their behaviour developmental delay in terms of emotional progress Sexual pain or itching in the genital area bruising or bleeding near genital area sexually transmitted disease vaginal discharge or infection stomach discomfort when walking or sitting down pregnancy sudden or unexplained changes in behaviour e.g. becoming aggressive or withdrawn fear of being left with a specific person or group of people having nightmares running away from home sexual knowledge which is beyond their age, or developmental level sexual drawings or language bedwetting eating problems such as overeating or anorexia self-harm or mutilation, sometimes leading to suicide attempts saying they have secrets they cannot tell anyone substance or drug abuse suddenly having unexplained sources of money not allowed to have friends (particularly in adolescence) acting in a sexually explicit way towards adults Neglect constant hunger, sometimes stealing food from other children constantly or ‘smelly’ loss of weight, or constantly underweight inappropriate clothing for the conditions complaining of being tired all the time not requesting medical assistance and/or failing to attend appointments having few friends mentioning being left alone or unsupervised
INSTRUCTIONS FOR ACCESSING LCC DOCUMENTS ONLINE Lansing Community College posts Invitations for Bid (IFB) and Request for Proposals (RFP) online at the State of Michigan Bid System All bid documents, including addendums, and questions and answers are available online. In to access these documents you will need to register. Registration is free to view documents however; to receive email notification you will need to pay a modest fee. Once registered, you will be able to view and print all bidding documents associated with a competitive bid. STEP-BY-STEP INSTRUCTIONS: STEP 1: Go to www.bid4michigan.com You will see the following message: The of Michigan Bid System Welcome to the State of Michigan Bid System (Bid4Michigan.com)! Department of Management and Budget (DMB) Purchasing Operations has implemented this system for faster and easier posting and notification of bid information to the public. Companies interested in doing business with the State will have access to all State Department and many Community College bid information from this website. This system provides instant access to all of our Bids, RFI's, RFP's, Quotes, Addenda and Awards online. In addition to DMB Purchasing Operations, other departments are expected to join in the future, so stay with us to watch us grow! Effective Monday, November 17, 2008, vendors must register to access open solicitation information, by clicking on the "Vendor Registration" link above. If you need assistance when registering, please click here to contact IPT. IPT provides all customer and technical support for the State of Michigan Bid System (Bid4Michigan.com) and will be happy to assist you during normal business hours (8:00 A.M. - 8:00 P.M. Eastern Time). We look forward to providing our vendors with more bid information, with less paperwork, and an easier method of doing business with us. We are excited about implementing this system and look forward to your participation. STEP 2: Vendors must select a registration option before they will receive access to bid opportunities. Your choices are: 1. Email Notification Services for $49.95 per year.
Objective #2: Beginning July 7, 2014 and continuing through June 30, 2015, all instructors will be given 30 minutes prior to class for instructional planning time. This will occur Monday-Thursday, weekly. Action Steps Person Resources Needed Monday-Thursday, instructors will sign a log to document proof they have used their planning time. Daily Instructor Log book for instructors kept by Lead Instructor Lead Instructor will ensure instructor’s complete planning time and report non-compliance to Program Director. Daily/as applicable Lead Instructor Log book for instructors to sign Objective #3: Throughout the 2014-15 fiscal years, required staff will participate in Professional Development and given time during their regular work day to complete requirements. If necessary, a substitute will be available to cover for the instructor. Lead Instructors or Program Director will be available if assistance is needed to complete requirements. Action Steps Person Needed All required staff will register for PD determined by the KYAE PD Catalog and participate in Study Circles. TBD by KYAE Instructor KYAE PD catalog Angel account All staff will participate in PD TBD by KYAE Instructor Account Lead Instructor will collect proof of registration and completion forms from instructors. These will be turned in to program director As available Lead Instructor or Program Director Verify Angel Account through email notifications. Lead Instructor will ensure that all instructors As needed Lead Instructor or Program Director View instructor demonstrating the use of
Campsite Capacity Car Park Capacity Venue Timings and Capacities Temporary Demountable Structures Erection & Maintenance of Structures Structural Safety & Wind Fire Safety of Materials Power Supply & Electrical Equipment Generators Electrical Installations & Appliances Site Lighting Fire Safety Fire Fighting Equipment Fire Safety Checks Raising the Alarm Preventative Measures Fireworks & Sparklers Emergency Services Rendezvous Point Provisions for Disabled People Crowd Management Audience Number Control Police SIA Licensed Security Team Stewards VIPs Accreditation Security Searches Missing Persons or Property Alcohol & Bars Designated Premises Supervisor Bar Operating Times Challenge 25 Event Website & Social Media PA Systems Loud Hailers Signage Medical First Aid & Welfare Medical Equipment & Staff Provisions Nearest Hospitals Refuse & Recycling Attendee Waste Page 3
INVESTIGATION OBSERVATION APPLICATION ST1 Explore simple mechanisms and structures to investigate how they work ST2 Explore in order to collect data ST3 Explore and investigate in order to collect data, analyse it and identify patterns ST4 Ask questions that can be answered by different types of investigative activity and decide the best approach to use ST5 Explore and explain how significant innovations and inventions have come about and how they have changed the way people live and use ideas from other cultures and times to inform their own experiments, investigations and designs ST6 Describe and compare observations and findings ST7 Capture, record and analyse data using a range of instruments, including sensors ST8 Sort, group and identify familiar living things and materials according to observable features and properties ST9 Make and record accurate measurements and detailed observations, presenting them appropriately and analyse, interpret and them ST10 Apply knowledge and understanding in practical work ST11 Sort, group and apply information using ICT to inform investigations, designs and made products ST12 Give instructions to make things happen programmable devices ST13 Devise simple criteria to evaluate approaches, products and outcomes
Other Requirements: Subject to electrical and flammable/explosive gas hazards. May be exposed to infectious and contagious diseases. May be in contact with patients under a wide variety of circumstances. Able to handle emergency or crisis situations. May occasionally be subjected to irregular hours. May be exposed to respiratory risks and safety sensitive situations. May be required to wear protective equipment as necessary. Possesses problem solving skills of the type and at a level necessary to accomplish the job. Demonstrates good time management and organizational skills. Visual and Hearing Requirements: Yes--Must be able to see with corrective eye wear Yes--Must be able to hear clearly with assistance The above statements reflect the general details necessary to describe the principal functions of the job as identified, and shall not be considered as a detailed description of all work requirements that may be inherent in the position. The Health Care Professional will receive or have access to information patient/client medical records ("Patient Information"), all of which is confidential property. The Health Care Professional agrees to keep all Patient Information in strictest confidence at all times. At no time during or after work status will the Health Care Professional use or disclose to any person any Patient Information made available to them in the course of their work status. Immediately upon the termination of work status, or upon request by the EOMC, the Health Care Professional will return all Patient Information and other materials or property in their possession, including all copies thereof, in whatever form they exist. Violation of confidentiality is cause for disciplinary action, including immediate termination.
Shareholder’s wealth creation in India post deregulation of petrol prices *Dr. Shashank Bhushan Lall ** Shubhadeep Chakraborty ________________________________________________________________________ Abstract: The study examines the effect of deregulation of petrol prices upon the wealth creation process of the shareholders of the Indian oil marketing companies. The Government of India has deregulated the petrol prices since 25th June 2010 and has allowed the oil marketing companies to link the retail selling prices of petrol to the market. The liberty in fixation of prices has a long lasting impact upon the wealth creation possibility of the shareholders of the oil marketing companies. International crude prices have off late been caught in a bearish trend which has pushed the international crude oil prices to new lows. This has reduced the import cost of crude oil for India and has helped in taming the inflationary trends in our country. Indian oil marketing companies too have benefited from this bearish trend as their under recoveries have come down considerably. Efficient cost management and free pricings of petrol have helped in increasing share price returns and creation of wealth for the shareholders of these companies. With partial deregulation the finances of Government of India has improved a lot due to huge savings in oil subsidies. The results of petrol deregulation is so positive that The Government of India is seriously contemplating about deregulating the diesel too from her control and make the retail selling price of diesel market linked. Key words: Deregulation, Petrol prices, wealth maximization, oil marketing companies * Dr.. Shashank Bhushan Lall is an Associate Professor at Patna University, Patna. (E): lallshashankbhushan@gmail.com, (M):+91 94310 77491 **Shubhadeep Chakraborty is an Assistant Professor in the area of Finance at Amity Patna. (E): , (M): +91 99312 37224
Xµ=∑X/N = 3886.20/55 = 70.65 ∑(x-xµ)= 0.45 Yµ=∑Y/N = 16757.19/55 =304.67 ∑(Y-Yµ) = 0.34 ∑(x-xµ)² = 2528.9 ∑(Y-Yµ)² = 278287.7 ∑((x-xµ)(Y- Yµ)= 2024.14 Corr (x, y) = 0.0763 B) Calculation of regression coefficient with the above variables: Testing Y on X byx= 111327.7-0.153/ 139089.5-.2025= 0.80 Testing X on Y
SHUTTLE STATION Commander- Responsible for all activities and crew members aboard the shuttle. Maintains communication with CAPCOM. Chief Engineer- Responsible for all activities and crew members aboard the station. Maintains communication with CAPCOM. Pilot- Second in command after Commander. Responsible for launch, landing and assisting the Commander in any way necessary. Navigator- Second in command after Chief Engineer. Responsible for launch, landing and assisting the Chief Engineer in any way necessary. Computer Specialist - Responsible for maintaining the computers on board, typing and transmitting completed documents. Technology Specialist -- Responsible for maintaining the computers on board, typing and transmitting completed documents. Computer Scientist- Works cooperatively with Computer Specialist I to complete tasks assigned. Technology Engineer- Works cooperatively with Technology Specialist I to complete tasks assigned. Communication Specialist- Manages all materials aboard the shuttle. Responsible for all activities/materials incoming and outgoing. Must be organized. Payload Specialist- Manages all materials aboard the shuttle. Responsible for all activities/materials incoming and outgoing. Must be organized. Research Specialist- Responsible for providing crew members with information for specific tasks. Mission Engineer- Serves as a problem solving expert. Good with details. Math Specialist- Serves as a problem- solving expert. Mission Scientist- Serves as a expert. Medical Specialist- Responsible for monitoring pulse and temperature for all shuttle crew members and completing scientific investigations in the medical field. Medical Specialist- Responsible for monitoring pulse and temperature for all shuttle crew members and completing scientific investigations in the medical field.
If the user is not satisfied by the developed prototype, then a new prototype is developed. This process goes on a perfect prototype is developed. Thus it becomes expensive and time consuming. The developer loses focus of the real purpose of software so it effect on the quality of software. For example developers may use inefficient algorithms and inappropriate programming languages while developing the prototype. Prototyping can lead to false expectations. For example the customer believes that the development of final system is finished when it is not. The primary goal of prototyping is speedy development so the system can be developed in series without considering integration of all components. 1.8.2.2 Spiral Model or Process Model:- The spiral model is software development model developed by Boehm in 1988. Instead of representing the software process as a sequence of activities with backtracking from one activity to another, the process is represented as a spiral. Each loop of spiral represents a phase of the software process. Spiral model can be defined as a ,“ a model of the software development process in which the activities like requirement analysis,coding,integration and testing are performed iteratively until the software is complete”. The spiral model is useful in following situation:- When development of project starts, it may be possible that work may be stopped due to any reason.in such cases what step must be taken to solve the problem should be known. Which path should be followed for particular procedure must be known in advance to the development team.so the work will not be stopped. Spiral helps us in above situation. It is useful for identifying and eliminating the high risks. The spiral contains four stages and each stage is represented by one quadrant of a Cartesian diagram. The radius of spiral represents the cost acquired in the process. The four major activities of spiral model are:-
The Health Insurance Portability and Accountability Act (HIPAA) of 1996 allows, in limited circumstances and with appropriate approvals, disclosure of Protected Health Information (PHI) by a Covered Entity without the patient’s explicit authorization for research purposes (45 CFR 164.512(i)). However, these disclosures must be tracked through an Accounting of Disclosures documentation process (45 CFR 164.528(b)(4)(i)). At UMass Medical School/UMass Memorial Health Care, if the number of disclosures is greater than or equal to 50 (individual patient records), researchers may either 1) document access to each record through the required disclosure process or 2) use a Summary Accounting process, which must contain the information requested below. Use this form if pursuant to your IRB-approved research protocol, Memorial will be disclosing 50 or more records to you for research purposes. UMass Medical School, the entity with responsibility for approval of human research activities, has agreed to assist UMass Memorial in facilitation of the summary disclosure accounting process. Individual completing the form: Contact information: Telephone: Email: Project Name Docket # PI Name, Address & Contact Phone # Plain language, short description of and purpose for research Criteria for selecting particular records (i.e. diabetics with PHI to be Accessed (i.e. Demographics, labs, imaging) Type of Waiver (check applicable, below) Sponsor Name, Address & Contact Phone # Time Frame (access start & projected stop to (mm/dd/yyyy) Partial Waiver for Recruitment/Participant Identification Full Waiver Other: Please complete and return this form via email to: The above information will be stored by UMass Medical School and provided to individuals in coordination with UMass Memorial Health Care upon request. If there are any changes to the above information during the course of the research, or if you have any questions about disclosure accounting requirements, please contact the UMMS Sr. Privacy Officer at the email above or by calling (508) 856-5508.
2B. Alternate Teaching Routing 2 – Segmentation with soundboxes – Say It Move It Segmenting Words using Say It - Move It We are going to stretch some words and say the sounds slowly. Each time I say a sound, I’ll move a chip. Watch me. The first word is hut. I’ll say it – move it. /h/ /uuu/ /u/ Do it with me. hut. What word? Now say it and move it (prompt: Say the word slowly. Move a chip each time you say a sound. ) Repeat with: (a) lamp, desk, must; (b) last, bump, fist; (c) sand, mask, mint Use the soundboxes that you printed and the pennies/chips you brought to class. [Compare to Bursuck & Damer - Table 3.3] New Letter Sounds This is the new sound. [sh says /sh sh . [point to letters] 2. What sound? [touch under letters] 4. Let’s practice saying our sounds. Look at the letters in line 1. What sound? 5. Sound? Let’s practice the sounds in line 2. Correct and repeat as necessary. sh . 1. sh i s m ch 2. a sh n th i 3. g t sh p th 4. u d i ch o
The Information provided will be reviewed by MM Tender Team. which led to early termination of that prior contract, damages or other comparable sanctions? 3.2 If you have answered Yes to any of the above (3.1), explain what measures been taken to demonstrate the reliability of the organisation despite the existence of a relevant ground for exclusion? (Self-Cleaning) Free Text Category 4 Insurance 4.1 Please confirm if you currently have, or are willing to commit to the £5 million pounds minimum required level of Employers Liability Insurance applicable for each and every occurrence. Yes No N/A Willing to Commit to taking out insurance to the required level if awarded the contract If no, automatic exclusion. If you answer N/A, please state why. Note that it is a legal requirement that all companies hold Employer’s Liability Insurance of £5 million as a minimum. This is not applicable to Sole Traders. 4.2 Please confirm if you currently have, or are willing to commit to the £5 million pounds minimum required level of Public Liability Insurance applicable for each and every occurrence. Yes No Willing to Commit to taking out insurance to the required if awarded the contract If no, automatic exclusion.
Matrix of regulatory framework and key features of audit committees Area Audit oversight and selection Composition and expertise United States The SOX and its rules set out specific activities required of a listed company’s audit committee relating to the external auditor. The audit committee shall be responsible for the following audit oversight activities: Appointment, setting the compensation and retention of the external auditor; Overseeing the work of the external auditor in preparing and issuing any audit report including resolving any disagreements between the management and the audit firm regarding financial reporting; Approval of all audit services and non-audit services; Evaluation of reports of external auditor on the following matters: (1) all critical accounting policies and practices to be used; (2) all alternative treatments of financial information within generally accepted accounting principles that have been discussed with management officials of the issuer, ramifications of the use of such alternative disclosures and treatments, and the treatment preferred by the registered public accounting firm; and (3) other material written communications between the registered public accounting firm and the management of the issuer, such as any management letter or schedule of unadjusted differences. Each audit committee must be composed of at least three members. Each member of the audit committee shall be a member of the board of directors, and shall otherwise be independent. In order to be considered to be independent, a member of an audit committee of an issuer may not, other than in his or her capacity as a member of the committee, the board of directors, or any other board committee: accept any consulting, advisory, or other compensatory fee from the issuer; or be an affiliated person of the issuer or any subsidiary thereof. Additional independence requirements under NASDAQ requirements – The member must not have participated in the preparation of the financial statements of the company or any current subsidiary at any time during the past three years. At least one member of the audit committee must be a financial expert or a person who has an understanding of financial statements and GAAP; experience in preparing, auditing, analyzing or evaluating financial statements of companies comparable to the company or experience in actively supervising one or more persons engaged in such activities; experience in applying GAAP to accounting for estimates, accruals and reserves; and an understanding of internal accounting controls, procedures for financial reporting and the functions of committees.
Fig. S3 The ions leaching in catalytic ozonation with different catalysts under initial pH=6.40 Reaction Condition: [Br-]=100 μg/L, [O3]=2 mg/L, [BZA]=10 mg/L, [Catalyst]=0.5 g/L. Fig. S4 The variation of pH in different oxidation processes under initial pH=6.40 Reaction Condition: [Br-]=100 μg/L, [O3]=2 mg/L, [BZA]=10 mg/L, [Catalyst]=0.5 g/L. Fig. S5 XPS survey spectrum of catalysts Fig. S6 EDX mapping image of used LaFeO3 (A); the elements of C, N, Br in the surface of fresh and used LaFeO3 (B-F); EDX mapping image of used LaCoO3 (G); the elements of C, N, Br in the surface of fresh and used LaFeO3 (H-L).
Nanomaterial characterization - Density of nanomaterial: 10.5 g/cm3 (silver) - Type of distribution: log-normal - of nanomaterial: sphere - Solubility: non-soluble Simulation - Exposure pattern: single event - Simulation duration: 1 per day - Inhalation rate: 0.61 m3/hr MPPD Airway morphometry - Species: human - Model: Yeh/Schum 5-lobe, Stochastic lung - FRC: 3,300 mL - URT volume: 50 mL Inhalation properties - Density: 10.5 g/cm3 - Diamter: polydisperse mode (0.01-10 μm) Exposure conditions - Constant exposure: acceleration of gravity (981.0 cm/s2), body orientation (upright), 82.0 μg/m3 for polydispersed mode), breathing frequency (12 /min), tidal volume (833 mL), inspiratory fraction (0.5), breathing scenario (nasal) Deposition/clearance - Deposition only Abbreviation: CEM, Consumer Exposure Model; ECETOC TRA, European Centre for Ecotoxicology and Toxicology of Chemicals Targeted Risk Assessment; ACH, Air exchange rate; CMD, Count median diameter; MMD, Mass median diameter; MMAD, Mass median aerodynamic diameter; CV, Coefficient of variation; FRC, Functional residual capacity; URT, Upper respiratory tract; ICRP, International Commission on Radiological Protection.
allusive – intimate, suggest, connote angry – mad, furious, irate bantering – good-natured teasing, ridicule, joking benevolent – magnanimous, generous, noble burlesque – mockery, sham, spoof, parody candid – clear, frank, genuine, sincere clinical - direct, detached, scientific, impersonal colloquial -common – ordinary, vernacular compassionate – kindly, sympathetic, benevolent complimentary – flattering, approving, laudatory concerned – touched, affected, influenced condescending – scornful, contemptuous, disdainful confident – positive, certain, assured contemptuous – pompous, arrogant, superior, haughty contentious – argumentative, quarrelsome, pugnacious cynical – adverse, suspicious, opposed, doubtful, dubious detached – separated, severed, apathetic didactic – pointed, bombastic, pompous, terse diffident – retiring, timid, hesitant, bashful disdainful – haughty, arrogant, supercilious dramatic – exciting, moving, sensational, emotional effusive – talkative, verbose, profuse elegiac – sad, mournful, plaintive (like an elegy) factious – dissident, rebellious, insubordinate factual – authentic, genuine, truthful fanciful – capricious, extravagant, whimsical flippant – offhand, facetious, frivolous impartial – equitable, unbiased, dispassionate incisive – cutting, biting, penetrating indignant – irritated, resentful inflammatory – irritate, arouse, resentful informative – acquaint, communicate, disclose insipid – flat, bland, tedious, banal (commonplace) insolent – insulting, brazen, rude, contemptuous
ironic – contradictory, implausible, incongruous irreverent – profane, impious, blasphemous, ungodly learned – skilled, experienced, professional lugubrious – gloomy, dismal, melancholy, somber maudlin – sentimental, gushing, insipid mock-heroic – mimicking courage (pretend) mock-serious – mimicking solemnity (pretend) moralistic – virtuous, righteous, blameless objective – impartial, detached, impersonal patronizing – condescending, scornful, disdainful pedantic – academic, bookish, scholastic petty – trivial, insignificant, narrow-minded pretentious – arrogant, boastful, conceited restrained – unwilling, hesitant, reluctant sardonic – cutting, biting, penetrating, satirical satiric – lampooning, facetious scornful – bitter, caustic, acrimonious, mordant sentimental – emotional, mushy, maudlin (tearful) somber – serious, gloomy, dismal, shadowy sympathetic – supportive, favorable, considerate taunting – contemptuous, insulting, derisive terse – concise, succinct, pithy, pointed turgid – pompous, bloated, swollen, distended urgent – compelling, demanding, imperative, pressing vibrant – resonant, active, resounding whimsical – flippant, frivolous, light-hearted, dainty
Full name Date of birth Family Contact address Parent/carers Gender Please list anyone else with parental responsibility and the relationship to the young person (eg step-dad) Landline Telephone Mobile Telephone Brothers and Sisters NHS number School Name (or other Educational Setting) Do you need an interpreter or other communication aid? If so, what? Language used at home Main communication method Religion Ethnicity:
A meeting of the Trust Board of Directors, in Public To be held on Tuesday, 26 July 2016, at 2.00 pm in the Boardroom, SGH For the purpose of transacting the business set out below 1. Apologies for Absence Dr James Whittingham, Chairman (5 mins) Verbal 2. Chairman’s Remarks Verbal 3. Declaration of Interests Dr James Whittingham, Chairman (5 mins) Verbal 4. To Approve the Minutes of the Previous Public Meeting held on 31 May 2016 Dr James Whittingham, Chairman (5 mins) Attached NLG(16)306 5. Matters Arising from the Minutes: None 6. Chief Executive’s Briefings: (25 mins) 6.1 Monthly Update, July 2016 Karen Jackson, Chief Executive Attached NLG(16)307 6.2 HLHF Update Karen Jackson, Chief Executive Verbal 7. Quality and Safety: 7.1 Patient Story Joanna Loughborough, Patient Experience Practitioner (5 mins) Verbal 7.2 Serious Incidents (SIs) including ‘Never Events’ Wendy Booth, Director of Performance Assurance & Trust Secretary (5 mins) Attached NLG(16)308 7.3 CQC Update Wendy Booth, Director of Performance Assurance & Trust Secretary (10 mins) Attached NLG(16)309 7.4 Monthly Capacity and Capability on our Wards Tara Filby, Chief Nurse (10 mins) Attached NLG(16)310 Sub Committees Supporting Papers: 7.5 Quality and Patient Experience Committee 7.5.1 QPEC Highlight Report, July 2016 (5 mins) Attached